A Conversation with Dr. Paolo Lusso
By Brooke Worthing
Thursday, June 27, 2019
First discovered in 1981, human immunodeficiency virus, or HIV, caused one of the most deadly and persistent epidemics in history. HIV destroys CD4+ T cells, a type of white blood cell essential for fighting infection. In doing so, HIV destroys the body’s ability to fight off disease, which often leads to life-threatening consequences.
Today, medications have allowed people living with HIV to lead healthier lives. However, HIV still remains a major public health concern and continues to be studied by researchers within the IRP and beyond.
IRP research has produced findings essential to the development of current HIV treatments and tools for diagnosis. However, there is still a lot left to learn. One recent IRP contribution to HIV research was a 2017 study led by IRP senior investigator Paolo Lusso, M.D., Ph.D., which suggests that treatments targeting a protein called integrin α4β7 could potentially become an addition to current treatment options for those with HIV, or provide new measures to prevent infection.
By Michael Gottesman
Thursday, December 15, 2016

Yasmine Belkaid, chief of the Mucosal Immunology Section in the NIAID Laboratory of Parasitic Diseases, has won the Sanofi–Institut Pasteur 2016 International Mid-Career Award for “outstanding research in the life sciences…contributing to progress in global public health,” announced on December 13, 2016 in Paris.
By IRP Staff Blogger
Thursday, December 24, 2015
At the beginning of every episode of the sci-fi series Star Trek, William Shatner repeated the words, “Space: the final frontier.” However, in all of Star Trek’s 79 episodes, Captain James T. Kirk and crew never encountered anything like the number and diversity of species that exists within the human microbiome.
